 | Up a level |
Sanz, Jaime; Labopin, Myriam; Pabst, Thomas; Versluis, Jurjen; Van Gorkom, Gwendolyn; Meijer, Ellen; Gedde-Dahl, Tobias; Montoro, Juan; Arcese, William; Pérez-Simón, Jose Antonio; Schaap, Nicolaas; Maertens, Johan; Vrhovac, Radovan; Lanza, Francesco; Gorin, Norbert Claude; Mohty, Mohamad; Ciceri, Fabio (2023). Etoposide plus cytarabine versus cyclophosphamide or melphalan in busulfan-based preparative regimens for autologous stem cell transplantation in adults with acute myeloid leukemia in first complete remission: a study from the Acute Leukemia Working Party of the EBMT. Bone marrow transplantation, 58(11), pp. 1197-1202. Nature Publishing Group 10.1038/s41409-023-02075-4
Shouval, Roni; Labopin, Myriam; Bomze, David; Baerlocher, Gabriela M.; Capria, Saveria; Blaise, Didier; Hänel, Mathias; Forcade, Edouard; Huynh, Anne; Saccardi, Riccardo; Milone, Giuseppe; Zuckerman, Tsila; Reményi, Péter; Versluis, Jurjen; Esteve, Jordi; Gorin, Norbert Claude; Mohty, Mohamad; Nagler, Arnon (2020). Risk stratification using FLT3 and NPM1 in acute myeloid leukemia patients autografted in first complete remission. Bone marrow transplantation, 55(12), pp. 2244-2253. Springer Nature 10.1038/s41409-020-0936-z
Gorin, Norbert Claude; Labopin, Myriam; Blaise, Didier; Dumas, Pierre-Yves; Pabst Müller, Thomas Niklaus; Trisolini, Silvia Maria; Arcese, William; Houhou, Mohamed; Mohty, Mohamad; Nagler, Arnon (2018). Optimizing the pretransplant regimen for autologous stem cell transplantation in acute myelogenous leukemia: Better outcomes with busulfan and melphalan compared with busulfan and cyclophosphamide in high risk patients autografted in first complete remission: A study from the acute leukemia working party of the EBMT. American journal of hematology, 93(7), pp. 859-866. Wiley-Liss 10.1002/ajh.25105
